<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526058</url>
  </required_header>
  <id_info>
    <org_study_id>LDLc-A-US2-0406</org_study_id>
    <nct_id>NCT00526058</nct_id>
  </id_info>
  <brief_title>(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol</brief_title>
  <acronym>FUTURA</acronym>
  <official_title>Randomized Multicenter Crossover Study to Compare the Plasmat® Futura Heparin Induced Extracorporeal Lower Density Lipo-Protein (LDL) Precipitation (H.E.L.P.) Apheresis System to the Approved Secura System in the Reduction of LDL-c in Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Medical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate that the performance of the modified
      Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved
      Plasmat® Secura H.E.L.P Apheresis System for use under the approved indication of the acute
      reduction of LDL-cholesterol from the plasma in populations for whom diet has been
      ineffective and maximum drug therapy has either been ineffective or not tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study endpoint is the change in percent measurements of the pre-to-post apheresis
      LDL measurements between the approved H.E.L.P. system and the modified H.E.L.P. system. The
      secondary study endpoints are clinical lab profiles and device parameters analyzed at
      specific time points throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.</measure>
    <time_frame>Blood samples for LDL-cholesterol determination will be obtained before and after each treatment from week 0 to week 24..</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change of the Pre and Post Treatment Value</measure>
    <time_frame>Assessment based on LDL-C values obtained pre-and post-treatment, analyzed from week 0 to week 24.</time_frame>
    <description>The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements. Blood samples for LDL-cholesterol determination will be obtained before and after each treatment. The pooled difference between the pre- and post-treatment LDL level for each apheresis machine will be reported as the primary endpoint for the system performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Lab Profiles (Pre- and Post-Treatment)</measure>
    <time_frame>Analyzed at specific time points throughout the study from week 0 to week 24.</time_frame>
    <description>Changes in pre- and post-treatment levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), total triglycerides, lipoprotein (a), fibrinogen, and C-reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Parameters</measure>
    <time_frame>Analyzed at specific time points throughout the study from week 0 to week 24.</time_frame>
    <description>Comparison of plasma flow rate recorded with both systems before treatment, after 500 mL of plasma treated, and at the end of each treatment session.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>A (Secura then Futura)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (Futura then Secura)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Secura then Futura</intervention_name>
    <description>Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.</description>
    <arm_group_label>A (Secura then Futura)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Futura then Secura</intervention_name>
    <description>Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.</description>
    <arm_group_label>B (Futura then Secura)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is between 25 and 70 years of age (inclusive) at the time of randomization.

          -  Subject is an appropriate candidate for H.E.L.P. apheresis treatment for
             hypercholesterolemia according to current Plasmat® Secura approval criteria.

          -  Subject has received a minimum of two consecutive bi-monthly* H.E.L.P. apheresis
             treatments using the Plasmat® Secura apheresis system &gt;30 days prior to the screening
             visit.

          -  Subject is willing to maintain cholesterol lowering dietary and drug therapies as
             prescribed through the course of the study.

          -  Subject is willing and able to provide written informed consent and Health Insurance
             Portability and Accountability Act (HIPAA) Waiver.

          -  Sterile, post-menopausal, or using acceptable birth control for the duration of the
             study. Acceptable birth control is defined as having a vasectomized, postmenopausal,
             or sterile partner; the ongoing use of approved hormonal contraceptives, barrier
             method, or an intrauterine device; or abstinence.

               -  Every 14 days (±2 days)

        Exclusion Criteria:

          -  A History of a known sensitivity to heparin or ethylene oxide.

          -  A history of hemorrhagic diathesis, bleeding/clotting disorder, thrombocytopenia
             (defined as platelet count &lt; 150 x109/L), or for whom the use of heparin would cause
             excessive or uncontrolled anticoagulation or for whom adequate anticoagulation cannot
             be safely achieved (ie., hemophilia, recent surgery, acute internal bleeding,
             gastrointestinal ulcers).

          -  Females who are pregnant or lactating.

          -  Subjects&lt; 106 lbs. or &lt;48.2 kg in body weight; or whose weight is &gt;1.5 times their
             ideal weight.

          -  Certain cardiac impairments such as congestive heart failure, major arrhythmia, or
             diastolic blood pressure greater than 100 mm/Hg on two separate occasions at least 24
             hours apart.

          -  Renal insufficiency defined as creatinine greater &gt;2.0 mg/dlL or is dependent upon
             renal dialysis.

          -  Untreated hypothyroidism; uncontrolled diabetes mellitus; or fasting triglycerides
             &gt;500 mg/dL.

          -  Serious systemic disease (e.g., advanced neoplasms, and acute hepatitis) including
             Immune system suppression or compromise, that could preclude survival to study
             completion.

          -  History of stroke within 6 months of the screening visit.

          -  Received thrombolytic treatment &lt; 7 days of screening.visit.

          -  Taken or requires a prohibited treatment &lt; 30 days prior to the Screening Visit, or
             requires a prohibited treatment at anytime during the course of the study.

          -  Neutropenia (neutrophil count &lt; 0.5 x109/L).

          -  History of liver disease or serum ALT and/or AST &gt; 2X upper limit of normal range.

          -  History of dementia.

          -  History of anemia (value outside the lower normal range).

          -  acetyl salicylic acid (ASA) &gt; 325 mg/day.

          -  Subject currently enrolled in another investigational study (does not apply to PMS for
             Secura device).

          -  Subject with any other medical condition that in the opinion of the investigator might
             put the subject at risk or interfere with his/her participation.

          -  Subject is unwilling or unable to comply with the protocol or to cooperate fully with
             the investigator or site personnel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Moriarty, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Thompson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs. 2002 Dec;25(12):1180-8.</citation>
    <PMID>12518963</PMID>
  </reference>
  <reference>
    <citation>Susca M. Heparin-Induced extracorporeal low-density lipoprotein precipitation futura, a new modification of HELP apheresis: technique and first clinical results. Ther Apher. 2001 Oct;5(5):387-93.</citation>
    <PMID>11778925</PMID>
  </reference>
  <reference>
    <citation>Schettler V, Monazahian M, Wieland E, Thomssen R, Müller GA. Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma virus load. Ther Apher. 2001 Oct;5(5):384-6.</citation>
    <PMID>11778924</PMID>
  </reference>
  <reference>
    <citation>Moriarty PM, Gibson CA, Shih J, Matias MS. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis. 2001 Oct;158(2):495-8.</citation>
    <PMID>11583732</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 5, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <results_first_submitted>May 25, 2010</results_first_submitted>
  <results_first_submitted_qc>July 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2010</results_first_posted>
  <last_update_submitted>August 17, 2018</last_update_submitted>
  <last_update_submitted_qc>August 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heparin</keyword>
  <keyword>Extracorporeal</keyword>
  <keyword>Low Density Lipo-Protein (LDL) Cholesterol</keyword>
  <keyword>Apheresis</keyword>
  <keyword>Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Secura</title>
          <description>Randomized first to the approved Plasmat® Secura apheresis system then Plasmat® Futura apheresis system.</description>
        </group>
        <group group_id="P2">
          <title>Futura</title>
          <description>Randomized first to the approved Plasmat® Futura apheresis system then Plasmat® Secura apheresis system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period: First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period: Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Secura</title>
          <description>Randomized first to the approved Plasmat® Secura apheresis system then Plasmat® Futura apheresis system.</description>
        </group>
        <group group_id="B2">
          <title>Futura</title>
          <description>Randomized first to the approved Plasmat® Futura apheresis system then Plasmat® Secura apheresis system.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="7.76"/>
                    <measurement group_id="B2" value="59.7" spread="9.15"/>
                    <measurement group_id="B3" value="58.3" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.</title>
        <time_frame>Blood samples for LDL-cholesterol determination will be obtained before and after each treatment from week 0 to week 24..</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secura</title>
            <description>Data for all 18 subjects; regardless of treatment sequence (Secura-Futura or Futura-Secura)</description>
          </group>
          <group group_id="O2">
            <title>Futura</title>
            <description>Data for all 18 subjects; regardless of treatment sequence (Secura-Futura or Futura-Secura)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P. System.</title>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.28" lower_limit="38.6" upper_limit="71.9"/>
                    <measurement group_id="O2" value="52.89" lower_limit="33.3" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change of the Pre and Post Treatment Value</title>
        <description>The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements. Blood samples for LDL-cholesterol determination will be obtained before and after each treatment. The pooled difference between the pre- and post-treatment LDL level for each apheresis machine will be reported as the primary endpoint for the system performance.</description>
        <time_frame>Assessment based on LDL-C values obtained pre-and post-treatment, analyzed from week 0 to week 24.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secura</title>
            <description>Data for all 18 subjects; regardless of treatment sequence (Secura-Futura or Futura-Secura)</description>
          </group>
          <group group_id="O2">
            <title>Futura</title>
            <description>Data for all 18 subjects; regardless of treatment sequence (Secura-Futura or Futura-Secura)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change of the Pre and Post Treatment Value</title>
          <description>The primary study endpoint is the change in percent measurements of the pre-to-post apheresis LDL measurements. Blood samples for LDL-cholesterol determination will be obtained before and after each treatment. The pooled difference between the pre- and post-treatment LDL level for each apheresis machine will be reported as the primary endpoint for the system performance.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.28" spread="9.783"/>
                    <measurement group_id="O2" value="52.89" spread="8.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of the Futura system to the Secura system would be demonstrated if the upper bound of the 90% confidence interval (CI) for the difference between the two systems (Secura-Futura) in percent change of LDL-C measurements from pre- to post-treatment is less than the noninferiority margin 5.7%.</non_inferiority_desc>
            <p_value>0.005</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Lab Profiles (Pre- and Post-Treatment)</title>
        <description>Changes in pre- and post-treatment levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), total triglycerides, lipoprotein (a), fibrinogen, and C-reactive protein.</description>
        <time_frame>Analyzed at specific time points throughout the study from week 0 to week 24.</time_frame>
        <population>Data for all 18 subjects; regardless of treatment sequence</population>
        <group_list>
          <group group_id="O1">
            <title>Secura</title>
            <description>Data for all 18 subjects; regardless of treatment sequence (Secura-Futura or Futura-Secura)</description>
          </group>
          <group group_id="O2">
            <title>Futura</title>
            <description>Data for all 18 subjects; regardless of treatment sequence (Secura-Futura or Futura-Secura)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Lab Profiles (Pre- and Post-Treatment)</title>
          <description>Changes in pre- and post-treatment levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), total triglycerides, lipoprotein (a), fibrinogen, and C-reactive protein.</description>
          <population>Data for all 18 subjects; regardless of treatment sequence</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.17" lower_limit="40.1" upper_limit="77.1"/>
                    <measurement group_id="O2" value="71.46" lower_limit="40.8" upper_limit="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.23" lower_limit="40.4" upper_limit="62.0"/>
                    <measurement group_id="O2" value="48.12" lower_limit="34.6" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.82" lower_limit="5.6" upper_limit="19.2"/>
                    <measurement group_id="O2" value="7.41" lower_limit="-3.8" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.14" lower_limit="16.5" upper_limit="76.3"/>
                    <measurement group_id="O2" value="62.65" lower_limit="-13.2" upper_limit="89.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipoprotein (a)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.25" lower_limit="43.5" upper_limit="74.4"/>
                    <measurement group_id="O2" value="49.68" lower_limit="-19.5" upper_limit="74.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrinogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.81" lower_limit="38.0" upper_limit="70.8"/>
                    <measurement group_id="O2" value="52.00" lower_limit="30.9" upper_limit="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-Reactive Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.59" lower_limit="45.2" upper_limit="67.7"/>
                    <measurement group_id="O2" value="48.88" lower_limit="35.0" upper_limit="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Parameters</title>
        <description>Comparison of plasma flow rate recorded with both systems before treatment, after 500 mL of plasma treated, and at the end of each treatment session.</description>
        <time_frame>Analyzed at specific time points throughout the study from week 0 to week 24.</time_frame>
        <population>Data for all 18 subjects; regardless of treatment sequence</population>
        <group_list>
          <group group_id="O1">
            <title>Secura</title>
            <description>Data for all 18 subjects; regardless of treatment sequence (Secura-Futura or Futura-Secura)</description>
          </group>
          <group group_id="O2">
            <title>Futura</title>
            <description>Data for all 18 subjects; regardless of treatment sequence (Secura-Futura or Futura-Secura)</description>
          </group>
        </group_list>
        <measure>
          <title>Device Parameters</title>
          <description>Comparison of plasma flow rate recorded with both systems before treatment, after 500 mL of plasma treated, and at the end of each treatment session.</description>
          <population>Data for all 18 subjects; regardless of treatment sequence</population>
          <units>flow rate (mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of Session; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.11" spread="9.380"/>
                    <measurement group_id="O2" value="12.39" spread="5.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Session; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.41" spread="10.978"/>
                    <measurement group_id="O2" value="8.89" spread="4.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Session; Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.00" spread="13.711"/>
                    <measurement group_id="O2" value="9.67" spread="3.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Session; Session 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.35" spread="8.838"/>
                    <measurement group_id="O2" value="9.17" spread="5.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Session; Session 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.29" spread="6.049"/>
                    <measurement group_id="O2" value="10.12" spread="3.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Start of Session; Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.61" spread="7.920"/>
                    <measurement group_id="O2" value="8.39" spread="3.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 500mL; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.67" spread="6.380"/>
                    <measurement group_id="O2" value="23.44" spread="2.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 500mL; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.59" spread="5.938"/>
                    <measurement group_id="O2" value="22.50" spread="3.552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 500mL; Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.61" spread="4.354"/>
                    <measurement group_id="O2" value="22.71" spread="3.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 500mL; Session 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.11" spread="3.216"/>
                    <measurement group_id="O2" value="23.11" spread="4.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 500mL; Session 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.67" spread="5.018"/>
                    <measurement group_id="O2" value="21.41" spread="3.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 500mL; Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.72" spread="8.456"/>
                    <measurement group_id="O2" value="23.72" spread="2.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of session; Session 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.24" spread="16.510"/>
                    <measurement group_id="O2" value="32.24" spread="17.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of session; Session 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.87" spread="16.587"/>
                    <measurement group_id="O2" value="28.44" spread="8.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of session; Session 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.17" spread="15.946"/>
                    <measurement group_id="O2" value="26.44" spread="9.281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of session; Session 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.00" spread="15.326"/>
                    <measurement group_id="O2" value="23.29" spread="7.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of session; Session 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.28" spread="12.750"/>
                    <measurement group_id="O2" value="21.50" spread="10.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of session; Session 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.59" spread="15.133"/>
                    <measurement group_id="O2" value="29.06" spread="5.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Secura</title>
          <description>Randomized first to the approved Plasmat® Secura apheresis system then Plasmat® Futura apheresis system.</description>
        </group>
        <group group_id="E2">
          <title>Futura</title>
          <description>Randomized first to the approved Plasmat® Futura apheresis system then Plasmat® Secura apheresis system.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myocardial Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>stomach discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>device breakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>device failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>device malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>medical device complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>breath sounds abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>serum ferritin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>nasal mucosal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>nasal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Site may publish its own results of the FUTURA Trial after a cooperative publication or 12 months after Sponsor's final evaluation of all the FUTURA Trial data from all sites, whichever occurs first. At least 90 days prior to submitting a manuscript to a publisher or other outside persons or prior to any public presentation, a copy of the abstract, manuscript, or presentation will be provided to Sponsor for review and comment. Sponsor shall have said 90 day period to respond w/ comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin Minnich, Manager Clinical Affairs/Safety Officer</name_or_title>
      <organization>B. Braun Medical Inc.</organization>
      <phone>610-596-2358</phone>
      <email>kevin.minnich@bbraun.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

